About 5 results found for searched term "Gefitinib" (0.05 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1749 | Gefitinib | EGFR/HER2 |
| ZD-1839, Iressa | ||
| Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. | ||
| M5679 | Gefitinib HCl | EGFR/HER2 |
| ZD-1839 hydrochloride | ||
| Gefitinib Hcl(ZD-1839 Hcl) is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR. | ||
| M14871 | Gefitinib-based PROTAC 3 | PROTAC |
| Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a von Hippel-Lindau ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively. | ||
| M39071 | Gefitinib impurity 1 | Metabolite/Endogenous Metabolite |
| Gefitinib impurity 1 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM). | ||
| M42084 | Gefitinib N-oxide hydrochloride | EGFR/HER2 |
| Gefitinib N-oxide hydrochloride is the N-oxide derivative of Gefitinib. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
